CAR spacers: Not just filling space.
作者信息
Brown Michael P
机构信息
Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA 5000, Australia; RAH Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia; Adelaide Medical School, The University of Adelaide, Adelaide, SA 5005, Australia.
出版信息
Mol Ther. 2024 Oct 2;32(10):3207-3208. doi: 10.1016/j.ymthe.2024.09.001. Epub 2024 Sep 17.
Abstract
摘要
相似文献
1
CAR spacers: Not just filling space.嵌合抗原受体（CAR）间隔物：不只是填充空间。
Mol Ther. 2024 Oct 2;32(10):3207-3208. doi: 10.1016/j.ymthe.2024.09.001. Epub 2024 Sep 17.
2
The invisible hand: How epigenetics shapes CAR T cell destiny.无形之手：表观遗传学如何塑造嵌合抗原受体T细胞的命运。
Mol Ther. 2024 Jun 5;32(6):1614-1616. doi: 10.1016/j.ymthe.2024.05.007. Epub 2024 May 17.
3
Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.实体瘤和年龄相关病症中的衰老细胞裂解性嵌合抗原受体T细胞
Mol Ther. 2020 Oct 7;28(10):2108-2110. doi: 10.1016/j.ymthe.2020.08.011. Epub 2020 Aug 25.
4
Cancer-fighting CAR T cells could be made inside body with viral injection.抗癌嵌合抗原受体T细胞可通过病毒注射在体内生成。
Nature. 2024 Jan;625(7994):225-226. doi: 10.1038/d41586-023-03969-5.
5
Highlight of 2023: Virtues and vices of CD4 CAR T cells.2023 年的亮点：CD4 CAR T 细胞的优缺点。
Immunol Cell Biol. 2024 Jul;102(6):432-436. doi: 10.1111/imcb.12764. Epub 2024 Apr 24.
6
Using TCR-CAR dual signaling for precise cancer targeting.利用TCR-CAR双信号进行精准癌症靶向治疗。
Trends Immunol. 2025 Jun;46(6):435-437. doi: 10.1016/j.it.2025.04.007. Epub 2025 May 13.
7
[NKG2D CAR-T cells as an immunotherapy in hepatocellular carcinoma].自然杀伤细胞群2成员D嵌合抗原受体T细胞作为肝细胞癌的一种免疫疗法
Med Sci (Paris). 2020 Jun-Jul;36(6-7):662-664. doi: 10.1051/medsci/2020118. Epub 2020 Jul 2.
8
Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells.使用嵌合抗原受体自然杀伤细胞（CAR NK细胞）克服肿瘤免疫治疗耐药性的新策略。
Front Immunol. 2025 May 29;16:1550652. doi: 10.3389/fimmu.2025.1550652. eCollection 2025.
9
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.多特异性靶向的合成锚蛋白重复序列嵌合抗原受体。
Clin Cancer Res. 2019 Dec 15;25(24):7506-7516. doi: 10.1158/1078-0432.CCR-19-1479. Epub 2019 Sep 23.
10
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.免疫细胞改造：创造更智能嵌合抗原受体 T 细胞的挑战和临床方法。
Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018.
本文引用的文献
1
Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models.新型 OX40 和 4-1BB 衍生间隔区增强了 CD30 阳性淋巴瘤模型中 CD30 CAR 的活性和安全性。
Mol Ther. 2024 Oct 2;32(10):3504-3521. doi: 10.1016/j.ymthe.2024.06.037. Epub 2024 Jun 29.
2
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.在 GD2 阳性转移性黑色素瘤和其他实体瘤患者中进行的 GD2 特异性 CAR-T 细胞的 1 期试验的安全性和生物学结果。
J Immunother Cancer. 2024 May 15;12(5):e008659. doi: 10.1136/jitc-2023-008659.
3
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.接受GD2嵌合抗原受体T细胞疗法的实体瘤患者中嵌合抗原受体T细胞扩增的免疫决定因素。
Cancer Cell. 2024 Jan 8;42(1):35-51.e8. doi: 10.1016/j.ccell.2023.11.011. Epub 2023 Dec 21.
4
Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR.理性蛋白设计产生的 CD20 CAR 比 CD19 CAR 具有更好的抗肿瘤疗效。
Cancer Immunol Res. 2023 Feb 3;11(2):150-163. doi: 10.1158/2326-6066.CIR-22-0504.
5
The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.嵌合抗原受体T细胞疗法在复发/难治性霍奇金淋巴瘤中的新兴作用
J Pers Med. 2022 Feb 1;12(2):197. doi: 10.3390/jpm12020197.
6
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.抗 CD30 CAR-T 细胞疗法在复发/难治性霍奇金淋巴瘤中的应用。
J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23.
7
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.嵌合抗原受体 T 细胞联合淋巴细胞耗竭和 PD-1 抑制治疗神经母细胞瘤患者。
Mol Ther. 2017 Sep 6;25(9):2214-2224. doi: 10.1016/j.ymthe.2017.05.012. Epub 2017 Jun 9.
8
Fine-tuning the CAR spacer improves T-cell potency.微调嵌合抗原受体（CAR）的间隔区可提高T细胞效力。
Oncoimmunology. 2016 Nov 8;5(12):e1253656. doi: 10.1080/2162402X.2016.1253656. eCollection 2016.
9
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.细胞外间隔区在嵌合免疫受体优化设计中的作用：四种不同单链抗体片段和抗原的评估
J Immunother. 2005 May-Jun;28(3):203-11. doi: 10.1097/01.cji.0000161397.96582.59.
Zotero 插件